These results, while limited by small sample size, suggest that combination immune checkpoint inhibition therapy may more effectively sensitize EGFR-mutant, PD-L1-expressing NSCLC to immune-mediated destruction than ICI monotherapy. Here, EGFR is linked to non-small cell lung carcinoma.